Monte Rosa Therapeutics bounded higher on Monday, as shares nearly doubled on a deal with Novartis to develop treatments for immune system conditions. Please watch the video at Investors.com ...

From what we can see, insiders were net buyers in Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE ) during the past 12 months. That is, insiders acquired the stock in greater numbers than they sold it.

MONTE ROSA THERAPEUTICS ($GLUE) posted quarterly earnings results on Thursday, March 20th. The company reported earnings of $0.23 per share, beating estimates of -$0. ...

The lengthening list of pharma alliances focused on molecular glue degraders has another entry after Novartis signed a deal with Monte Rosa Therapeutics worth up to $2.2 billion. The partnership ...

Roche seems determined to develop a commanding position in the emerging molecular glue category, signing up to a $2 billion partnership with Monte Rosa Therapeutics that includes a $50 million ...

Monte Rosa Therapeutics' stock dropped 17% after announcing MRT-2359's target shift to castration-resistant prostate cancer (CRPC) due to poor efficacy in lung and neuroendocrine cancers.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Upcoming Movies and TV shows Rotten Tomatoes Podcast Media News + More ...

From what we can see, insiders were net buyers in Monte Rosa Therapeutics, Inc.'s ( NASDAQ:GLUE ) during the past ...